SoftBank leads funding that could net up to $525M for Exscientia's AI drug platform aalidrus Wed, 04/28/2021 - 09:35.: With two partnered drugs in the clinic, Exscientia is reeling in up to $525 million to push its own pipeline into clinical testing and continue developing an artificial intelligence-based technology toward autonomous drug design. SoftBank Vision Fund 2 led the $225 million series D financing, in which a dozen other investors participated, including BlackRock, Novo Holdings, Bristol Myers Squibb and Mubadala Investment Company.